Targeting the mitochondrial VDAC in hepatocellular carcinoma using a polyclonal antibody-conjugated to a nitrosyl...

Area of Science:

• Inorganic Chemistry
• Cancer Biology
• Drug Delivery

Background:

• Ruthenium complexes offer a rational design approach for novel anti-cancer agents.
• Nitric oxide (NO) donor agents are explored for targeted cancer therapy.
• Bis(bipyridine) ruthenium complexes are a well-studied class for such applications.

Purpose of the Study:

• To synthesize and characterize a ruthenium complex, cis-[RuII(NO+)Cl(dcbpy)2]2-, conjugated to an anti-VDAC antibody.
• To evaluate the chemical properties and cytotoxicity of the conjugate against the HepG2 liver cancer cell line.
• To investigate the interaction of the complex with mitochondria as a potential anti-cancer mechanism.

Main Methods:

• Synthesis and characterization of the ruthenium complex-antibody conjugate.
• UV-visible spectroscopy and density functional theory (DFT) for structural analysis.
• Cytotoxicity assays using the HepG2 cell line to compare conjugate vs. free complex.

Main Results:

• The ruthenium complex was successfully conjugated to an anti-VDAC antibody.
• DFT calculations aided in assigning UV-visible bands and understanding biological effects.
• The cis-[RuII(NO+)Cl(dcbpy)2]3--anti-VDAC antibody conjugate exhibited up to 80% greater cytotoxicity than the free complex against HepG2 cells.

Conclusions:

• Ruthenium complex-antibody conjugates represent a promising strategy for targeted cancer therapy.
• Site-specific delivery of the NO-releasing complex via antibody targeting enhances anti-cancer efficacy.
• Mitochondrial interaction, facilitated by the antibody, may contribute to the observed enhanced cytotoxicity.